NR4A1 and breast cancer: HER2-positive breast cancer, which accounts for about 15%–20% of all breast cancers, is associated with a more aggressive clinical course and a poor prognosis compared with hormone receptor (HR)-positive, HER2-negative breast cancer (2, 3).